Roche reports full Scope 1 & 2 emissions under GHG Protocol with KPMG assurance. Scope 1&2 fell from 322 ktCO₂e (2022) to 175 ktCO₂e (2025)—46% absolute reduction in three years. Granular site-level breakdown and multi-year tracking since 2004 with halogenated hydrocarbon inventory at tonne level.

Roche quantifies Scope 3 across six categories using GHG Protocol hybrid methodology. Total emissions fell 20.5% (2022–2025). Supplier engagement increased 24% to 49% of suppliers by emissions with SBTs, targeting 70% by 2029. Scope 3 remains 95% of total footprint; full supplier data still in development.

Scope 1&2 declined 46% (2022–2025); total emissions 20.5% decline. Since 2004, 67% absolute reduction in Scope 1&2. Scope 3 Categories 11&12 fell 14%; Categories 3, 5, 6 remained flat at ~198–199 ktCO₂e. Multi-year consistency but full Scope 3 reduction acceleration needed.

Roche achieved 100% sustainable electricity in 2025 (86% in 2024) via hydropower, on-site solar, and grid renewables. Each site has decarbonisation roadmaps including geothermal and heat pumps. Scope 1 fossil fuel combustion (175 ktCO₂e combined S1&2) and 49% supplier SBT coverage remain limiting factors.

Roche published a Biodiversity Position supporting CBD and GBF principles, sources certified commodities, and is developing nature/water dependency methodologies. However, World Benchmarking Alliance found no biodiversity impact assessment in operations or supply chain, no disclosure of operations near sensitive areas, and no TNFD alignment.

Roche prohibits chemical/medicinal waste landfilling, operates solvent recycling, and embedded eco-design via Product Sustainability Performance tool with 50% footprint reduction target by 2029. Supplier expectations set for material reduction and recycling. Publicly available quantified circular economy metrics and plastic waste volumes remain limited.

Roche reports ~15 million m³ water withdrawal, consumption, and discharge based on meter readings since 2014. 83% returned to freshwater; heavy metals negligible. Wastewater includes TOC and ozone treatment for non-degradable contaminants. No absolute water reduction targets set; supplier engagement on water absent.

Roche achieved SBTi validation (April 2025)—first pharma with SBTi-validated net-zero and absolute-zero targets. Near-term (2029): 70% absolute S1&2 reduction; 22.5% Scope 3 selected reduction; 70% suppliers with SBTs. Long-term (2045): 90% absolute reduction across all scopes. Absolute zero for S1&2 by 2050 exceeds SBTi baseline.

Roche publishes annual Sustainability Report meeting Swiss CO Art. 964b with ESRS alignment and KPMG assurance. TCFD climate disclosures included; dedicated Chief Sustainability Officer at Group level. Board oversight confirmed. Annual data with detailed performance sheets published. Executive compensation linkage to sustainability targets and mission-locked governance not evident.

ViolationTracker records $433M penalties since 2000, primarily healthcare fraud, pricing, and antitrust—not environmental. No climate greenwashing lawsuits identified; InfluenceMap found limited direct climate engagement. However, Roche retains VCI membership, whose climate policy engagement is 'predominantly negative,' and has not published formal trade association alignment review.